IOL Chemicals and Pharmaceuticals Limited — Updates, 12-02-2025: Press Release

IOL Chemicals and Pharmaceuticals Ltd reported its financial results for the quarter and nine months ending December 31, 2024. The standalone total income was ₹527.37 Cr for Q3 FY25, declining slightly by 0.90% quarter-on-quarter and 0.26% year-on-year. EBITDA improved 6.15% sequentially to ₹50.94 Cr, although it dropped 22.98% compared to last year, leading to an EBITDA margin of 9.66%. PAT for the quarter stood at ₹20.55 Cr, reflecting a 7.31% increase QoQ but a significant drop of 11.54% YoY, resulting in a PAT margin of 3.90%.

The management expressed confidence in the company's performance despite market challenges, highlighting efforts in cost optimization and market diversification to drive growth. The Board has declared an interim dividend of ₹4 (40%) per share, with the record date set for February 18, 2025. Overall, the company's strategic initiatives and stable financials suggest a positive outlook, but investors should remain vigilant of market dynamics and pricing pressures.